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Oxidative stress is associated with the pathology of neurodegenerative diseases. 
Identification of small molecules capable of protecting against oxidative stress is therefore 
of significant importance. In this context, a library of 76 hydroxy flavones, methoxy 
flavones and their 4-thio analogues has been evaluated for neuroprotection against H2O2-
induced oxidative stress. This revealed the synthetic 7,8-dihydroxy 4-thioflavones as 
neuroprotective compounds, with 14d and 18d showing highest neuroprotective effects at 
lower concentrations (0.3 μM). Neuroprotection was found to be mediated via activation of 
the anti-apoptotic cell survival proteins of the ERK1/2 and PI3K/Akt pathways. Structure-
activity relationship analysis revealed the B-ring phenyl group as essential for greater 
neuroprotection. Replacing the 4-C=O moiety with a 4-C=S moiety also generally 
enhanced neuroprotection. 
2009 Elsevier Ltd. All rights reserved. 
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1 Introduction 
 
Increased levels of oxidative stress are closely linked with 
many neurodegenerative diseases such as Parkinson's 
disease, Alzheimer's disease, and Amyotrophic Lateral 
Sclerosis1–3. Whilst antioxidants have received attention as 
potential agents for managing such conditions, some clinical 
trials using recognised antioxidants such as vitamin E, vitamin 
C, pure scavenger molecules such as boldine, and NMDA 
receptor blockers, have resulted in conflicting results and 
conclusions4,5. It is now believed that antioxidants not only 
reduce oxidative stress, but can also halt beneficial cellular 
processes. Therefore, it has been hypothesised that restoring 
the redox equilibrium by activation of intracellular signals 
involved in cell survival is more important6 than solely 
restoring the redox equilibrium by direct scavenging of 
reactive oxygen species in the course of cellular oxidative 
stress. Hence, therapeutic strategies that aim to identify small 
molecules that confer neuroprotection against oxidative stress 
either by activating pro-survival regulatory pathways, or by 
increasing endogenous cellular antioxidant defences, may 
offer effective treatment for these neurodegenerative 
diseases7,8. Identification of novel neuroprotective agents with 
favourable pharmacokinetic profiles and CNS distribution is 
also of pivotal importance for a successful clinical translation.  
Flavones, a subclass of flavonoids, are polyphenolic 
phytochemicals that have been well recognised for their 
diverse pharmacological activities including 
neuroprotective9,10 activities. In particular, several 
epidemiological in vitro and in vivo studies have highlighted 
the potential of flavonoids as neuroprotective agents. For 
example, natural flavonoids such as fisetin8, luteolin, 
quercetin, myricetin and hesperetin4,11,12 have been reported to 
protect neurons against oxidative damage. Further, several 
synthetic flavones13,14 and thioflavones15 have been reported 
to limit neurodegeneration associated with a variety of 
neurological disorders, namely Alzheimer’s disease16 (AD) 
and Parkinson’s disease17 (PD).  Interestingly, flavonoids 
have been reported to increase cell survival in an oxidative 
stress model where scavenging antioxidants (vitamin E, 
boldine) failed to protect cells from the oxidative insult4. 
Also, growing bodies of evidence have attributed the 
neuroprotective abilities of flavonoids to their signalling 
regulation abilities18–21. Further, studies focusing on the 
blood–brain barrier (BBB) permeability of flavonoids have 
highlighted that the lipophilic flavonoids possess greater BBB 
permeability than the polar flavonoids22,23; the permeability 
potency of the compounds also correlated with their 
lipophilicity (log P)
24–26
. With our interest in developing 
novel flavone derivatives as therapeutic agents, we had 
previously synthesised and characterised a library of 76 
hydroxy flavones, methoxy flavones and their 4-thio 
derivatives27 (Figure-1). Intrigued by the neuroprotective 
potentials of flavones and by the higher lipophilicity of 4-
thioflavones and methoxy flavones than their corresponding 
hydroxy flavones, in this study, an assessment of the 
neuroprotective abilities of the library of 76 flavones 
presented herein was carried out.  Also, due to the absence of 
a systematic investigation of the effect of substitution of the 
4-carbonyl (4-C=O) group by a 4-thiocarbonyl (4-C=S) group 
on the neuroprotective activities of flavones, we aimed to 
explore the structure-activity relationships (SARs) of the 
library of 76 flavones presented herein
Figure 1. Structures of flavones investigated in this study.
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2 Materials and methods 
Please see supplementary information. 
3 Results and discussion 
3.1 Library design 
 As illustrated in Figure-1, the library of flavones is composed 
of three series. Each series contained methoxy flavones 
(designated a), hydroxy flavones (designated b), methoxy 4-
thioflavones (designated c) and hydroxy 4-thioflavones 
(designated d). The compounds in series-1 (1a-d to 5a-d) 
were derived from well-known flavones with different 
numbers and positions of hydroxyls. Series-2 was based on 
bioisosteric analogues of the B-ring of the active flavones 
from series-1 (6a-d to 11a-d). In series-3 further 
functionalization was incorporated via the inclusion of 
electron-withdrawing groups (EWGs) onto the B-ring (12a-d 
to 19a-d) (Figure-1). The purities of all compounds were 
established prior to evaluation, by reverse phase HPLC, and 
were found to be >95%.  
3.2 Neuroprotective evaluation 
All compounds were evaluated for their ability to protect 
neurons from H2O2-induced oxidative stress in an in vitro 
model using the SH-SY5Y human neuroblastoma cell line28,29. 
An appropriate concentration of H2O2 for inducing oxidative 
stress in SH-SY5Y cells was determined by exposing the SH-
SY5Y cells to various concentrations of H2O2 (5-500 µM) for 
18 h. From the cell viability assessment, using the MTT assay, 
it was found that H2O2 at 130 µM (IC50 value) induced a 50% 
reduction in the SH-SY5Y cell viability (Supplementary info, 
Figure-S1). Hence, this concentration (130 µM) was used for 
further experiments to induce oxidative stress in SH-SY5Y 
cells. Next, the SH-SY5Y cells were treated with each of the 
compounds at the physiologically relevant concentration of 3 
µM concentration30 for 24 h prior to exposure to H2O2 (18 h). 
The cell viability was then determined by the MTT assay 
(Figure-2).  
By comparing the neuroprotective activities of series-1, 
series-2 and series-3 flavones (1a-d to 19c-d) it was generally 
found that: - 
i) Flavones bearing catecholic hydroxyl (C-7,8 
hydroxyl, o-hydroxy) substitutions either on 
ring-A or -B were significantly more 
neuroprotective than those with m-hydroxyl 
substitutions. For example 2b and 2d with C-5,7 
hydroxyl (m-hydroxy) groups) were found to be 
inactive (cell viability < 50%) whereas 1b, 4b 
and 5b with catecholic  hydroxyl groups  confer 
neuroprotection by restoring the cell viability > 
80%.  This suggests that the catecholic hydroxyl 
substitution is indispensable for neuroprotective 
activity. 
ii) The B-ring phenyl group was vital for 
neuroprotective activity of catecholic flavones; 
replacing the B-ring phenyl group with its 
bioisosteres [series-2 (6b, 8b, 10b, 6d, 8d and 
10d); cell viability < 60%] was detrimental for 
neuroprotective activity but incorporation of 
electron withdrawing groups on the B-ring 
phenyl group [series-3 (12b, 14b, 16b, 12d, 14d 
and 18d); cell viability > 85%] was beneficial. 
iii) Methoxy flavones were less neuroprotective 
than their analogous hydroxyl flavones. 
iv) For the synthetic flavones in series 2 and 3, the 
4-thioflavones (C=S) [12f (cell viability = 97.4 ± 
4.3%), 14f (cell viability = 106.7 ± 1.2%), 16f 
(cell viability = 97.8 ± 2.6%) and 18f (cell 
viability = 105.8 ± 3.7%)] were significantly 
more neuroprotective than the flavones (C=O) 
[12d (cell viability = 88.8 ± 2.5%), 14d (cell 
viability = 93.4 ± 1.4%), 16d (cell viability = 
84.0 ± 3.6%), and 18d (cell viability = 84.6 ± 
1.6%)]. However, the opposite trend was evident 
for the natural flavones in series 1 [1d (cell 
viability = 96.2 ± 1.3%) vs 1f (cell viability = 
72.4 ± 1.2%); 4d (cell viability = 98.3 ± 2.1%) 
vs 4f (cell viability = 67.4 ± 1.3%)]. 
 
 
 
 
Figure 2. Neuroprotective effects of (A) Series-1 (1a-d to 5a-d) (B) 
Series-2 (6a-d to 11a-d) and (C) Series-3 (12a-d to 19a-d) at 3 µM 
concentration against H2O2-induced oxidative stress in SH-SY5Y 
cells. Cells without treatment serve as control. Cell viability was 
measured by MTT assay. Statistical significance was estimated by 
one-way ANOVA followed by Bonferroni’s post hoc test, (#)-
significance with respect to the control (p < 0.0001) and (*)-
significance with respect to H2O2 (*p < 0.05, **p < 0.01, ***p < 
0.001 and ****p < 0.0001). Colour coding: purple-methoxy flavone 
(-OMe, 4-C=O), blue-hydroxy flavone (-OH, 4-C=O), green-
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methoxy 4-thioflavone (-OMe, 4-C=S) and red-hydroxy 4-
thioflavone (-OH, 4-C=S).  
 
Compounds 1b, 4d, 12b, 12d, 14b, 14d, 16b, 16d, 18b and 
18d that exhibited the highest neuroprotective effects at the 
single dose of 3 µM were further evaluated at lower 
concentrations to determine their ability to exert neuronal 
protection against H2O2-induced oxidative stress. Whilst no 
significant protective effects were observed at lower 
concentrations for 1b, 4b, 12b, 12d, 14b, 16b, compounds 
14d and 18d were found to be effective even at 0.3 µM 
concentration (cell viability >70%) (Figure-3). Importantly, 
compounds 1b, 4d, 12b, 12d, 14d, 16b and 18d were found to 
be nontoxic to SH-SY5Y cells at 3 µM and 10 µM doses for 
24 h (as evidenced using the MTT assay). However, 
compound 16d caused 52% reduction in the cell viability at 
10 µM, p < 0.001 (Figure-4).  
 
Figure 3. Neuroprotective effects of (A) Compound-1b, (B) 
Compound-4b, (C) Compound-12b, (D) Compound-12d, (E) 
Compound-14b, (F) Compound-14d, (G) Compound-16b, (H) 
Compound-16d, (I) Compound-18b, and (J) Compound-18d in a 
dose dependent manner in the concentration range 0.1-3 µM against 
H2O2-induced oxidative stress in SH-SY5Y cells. Cells without 
treatment serve as control. Data are expressed as the mean ± standard 
error of the mean (SEM) (n = 3). Statistical significance was 
estimated by one-way ANOVA followed by Bonferroni’s post hoc 
test, (#)-significance with respect to the control (p < 0.0001) and (*)-
significance with respect to H2O2 (**p < 0.01and *** p < 0.001).  
Figure 4. Toxic effects of compounds 1b, 4d, 12b, 12d, 14b, 14d, 
16b, 16d, 18b and 18d evaluated at 3 and 10 µM concentrations 
against SH-SY5Y cells. Cells without treatment serve as control. 
Data are expressed as the mean ± standard error of the mean (SEM) 
(n = 3). Statistical significance was estimated with respect to the 
control by one-way ANOVA, followed by Bonferroni’s post hoc test 
(***p < 0.001). 
3.3 Molecular mechanism of neuroprotection  
Flavones can act either as a free radical scavenger 
(antioxidant) or can trigger intracellular pathways for cell 
survival. Therefore, to gain insight into the mechanism of 
neuroprotection, their antioxidant potentials and impact on 
certain intracellular signalling targets were explored.  
3.3.1 Antioxidant activity 
Flavones are very well known for their antioxidant 
activities31,32, therefore the antioxidant properties of flavones 
1b (7,8-dihydroxy flavone), 4b (luteolin, a well-known 
natural flavone) and compound-14b with a 4-C=O moiety, as 
well as the most neuroprotective 4-thioflavones (with 4-C=S) 
14d, 16d and 18d were studied. For this, the flavones were 
evaluated at their neuroprotective concentration of 3 M both 
for their ability to directly interact with free radicals (primary 
antioxidant activity) using a DPPH free radical scavenging 
assay and for their ability to bind to ferrous (Fe2+) ion that 
catalyses oxidation (secondary antioxidant activity), using a 
metal chelating assay (Table-1).  As shown in Table 1, all the 
aforementioned flavones showed very low scavenging activity 
(only up to 1.9% inhibition of DPPH radical) at 3 M. Also, 
based on previous reports on DPPH scavenging data for the 
well-known flavones (1b and 4d, Series-1), no correlation 
was found between the order of their neuroprotective abilities 
[1b (Cell viability-97%) > 4d (Cell viability-73%, p < 0.05)] 
and the order of their scavenging activity [DPPH radical 
scavenging activity- IC50-4d (11.04 ± 0.38 µM) > 1b (15.50 ± 
0.12 µM)]33. Since, in general, compounds with catechol 
groups are defined as effective metal chelators 34–36, the iron-
chelating ability of flavones 1b, 4d, 14b, 14d, 16d and 18d at 
3 µM was further studied. Interestingly, a low degree of Fe2+ 
chelation (only up to 5%) was exhibited by these flavones at 3 
M concentration (Table 1).  
Taken together, there was no observed correlation between 
the neuroprotective profiles and the antioxidant activities of 
flavones at their tested concentration. Therefore, it is possible 
that the flavones directly interact with cellular events leading 
to cell death after oxidative stress. Hence, the intracellular 
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signalling pathways triggered by flavones in oxidative-stress 
induced SH-SY5Y cells were probed. 
 
Table 1. Antioxidant activities of flavones 
Flavone 
Antioxidant activity at 3 µM concentrationa  
DPPH scavenging assay  
(Scavenging activity, %) 
Metal chelating assay 
(Fe2+ chelating activity, %) 
1b 1.4  0.2 3.7  1.0 
4b 1.9  0.2 3.4  0.4 
14b 1.4  0.5 3.7  1.2 
14d 1.7  0.2 5.0  1.6 
16d 1.6  0.6 4.4  1.7 
18d 1.3  0.2 3.9  0.4 
Ascorbic 
acidb 
1.3  0.5 - 
EDTAc - 6.9  0.4 
a Data expressed as Mean ± SEM, n = 3; bAscorbic acid was used as 
a reference standard for the DPPH scavenging assay, IC50 value of 
ascorbic acid for the inhibition of DPPH radical formation was 
established to be 330  0.5 µM (Supplementary info, Figure-S2); 
cEDTA was used as a reference standard for the metal chelating 
assay, IC50 value of EDTA in metal chelating assay was determined 
to be 42  0.8 µM (Supplementary info, Figure-S3).  
3.3.2 Intracellular signalling 
 Accumulative evidence has shown that flavonoids display 
signalling properties during neuroprotection12,21,37–40. Hence, 
the potential intracellular signalling involved in the 
neuroprotective function of flavones were probed. For this, 
the signal mediated in SH-SY5Y cells by the well-known 
compounds 1b, 4b (luteolin) and compound-14b with a 4-
C=O moiety, as well as the neuroprotective 4-thioflavones 
(with 4-C=S) 14d, 16d and 18d were studied. Pooled samples 
from three independent treatments of SH-SY5Y cells with and 
without H2O2 (130 µM), and with these compounds at 3 µM 
concentration for 24 h followed by the exposure to H2O2 (1 
h)38, were analysed using the PathScan® Intracellular 
Signalling Array Kit (Figure-5). These compounds were 
found to modulate the signalling molecules that are associated 
with cellular survival and apoptosis such as ERK1/2, mTOR, 
AMPKα and Akt targets such as Bad and PRAS40. Treatment 
of SH-SY5Y cells with H2O2 (130 µM) resulted in a marked 
reduction in phosphorylation of ERK1/2, mTOR, Bad and 
PRAS40. Pre-treatment with 7,8-dihydroxy flavones 
(containing 4-C=O) showed that compounds 1b and 4b were 
able to confer neuroprotection by the inhibition of apoptosis 
through restoration of Bad (a pro-apoptotic protein) 
phosphorylation (by inactivating its apoptotic activity), 
whereas, compound 14b was shown to elicit its activity 
through restoration of mTOR phosphorylation, which restores 
protein synthesis. In the case of 4-thioflavones, compound 
14d significantly restored phosphorylation of ERK1/2, 
mTOR, Bad and PRAS40 up to the same levels or higher than 
that observed in the control, along with activation of AMPKα. 
Also, compound 18d was found to restore phosphorylation of 
ERK1/2 and mTOR, along with activation of AMPKα, 
however, compound 16d showed restoration of Bad 
phosphorylation only. These results support the in vitro 
observations and suggest that the neuroprotective effects of 
flavones are mediated via ERK1/2 and PI3K/Akt/mTOR 
pathways and that these flavones differentially activate the 
pro-survival protein kinases based on their chemical structure. 
Also, a comparison of intracellular signalling of the 4-
thioflavone 14d with its corresponding flavone 14b highlights 
the beneficial influence of 4-C=S substitution on the 
neuroprotective activity. Thus, the enhanced neuroprotective 
effects of compounds 14d and 18d can be attributed to their 
potential to modulate multiple signalling targets. As several 
studies have highlighted compound-1b as a promising small 
molecular BDNF mimetic, with selective TrkB 
(Tropomyosin-related kinase B) receptor agonist activity41–47, 
it may be pertinent to explore the roles of compounds 14d and 
18d in the modulation of the TrkB receptor in the future. 
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 Figure 5. (A) Chemiluminescent array images of the PathScan 
Intracellular Signalling array kit revealing various phosphorylated in 
SH-SY5Ycells pre-treated with and without compounds 1b, 4b, 14b, 
14d, 16d and 18d at 3 µM for 24 h before exposure to H2O2 (130 
µM). Cells without treatment serve as control. (B) Bar chart 
representing the fold change in the integrated density of 
phosphorylated signalling nodes in the array image of SH-SY5Ycells 
pre-treated with and without compounds 1b, 4b, 14b, 14d, 16d and 
18d at 3 µM for 24 h before exposure to H2O2 (130 µM). Data are 
expressed as the mean ± standard error of the mean (SEM) (n = 4). 
Statistical significance was estimated with respect to the control (#) 
and with respect to H2O2 (*) by one-way ANOVA, followed by 
Bonferroni’s post hoc test (ns-not significant, *p < 0.05, **p < 0.01, 
***p < 0.001 and ****p < 0.001). (C) Molecular mechanism of 
action of 1b, 4b, 14b, 14d, 16d and 18d in SH-SY5Y cell line. 
 
3.3.3 In silico prediction of BBB permeability 
 For the flavones to be able to exert their neuroprotective 
effect clinically, permeation across the BBB is required. 
Therefore, BBB permeability scores were calculated for each 
flavone. These BBB permeability scores were then plotted 
against the neuroprotective ability to identify the most 
promising candidates (i.e. compounds with both high 
predicted permeation across the BBB and high 
neuroprotective activity, Figure-6). This showed that synthetic 
thioflavone compounds 14d and 18d possess both high 
neuroprotective ability (cell viability > 95%, neuroprotective 
even at 0.3 µM concentration) and high BBB permeability 
(BBB score > 0.02). In contrast, the natural/well-known 
flavones such as 7,8-dihydroxy flavone (1b), luteolin (4b) and 
quercetin (5b) were found to be neuroprotective but their poor 
BBB permeability scores might undermine the likelihood of 
achieving sufficiently high concentrations in the central 
nervous system. Therefore, the synthetic thioflavones 14d and 
18d can be considered as lead candidates for further design 
and development of neuroprotective agents. 
 
Figure 6. Graph represents BBB permeability of compounds 
(predicted BBB score) versus neuroprotective activity (cell viability) 
determined at 3 µM using the SH-SY5Y neuroblastoma cell line. 
The dashed line at x = 0.02 represents the threshold BBB-/BBB+ 
score and the dashed line at y = 50 represents 50% cell viability in 
SH-SY5Y cells exposed to H2O2.  Neuroprotective natural 
flavone/well-known flavones are highlighted in blue and the 
thioflavones that have been identified to be neuroprotective are 
highlighted in red. Lower left quadrant represents low 
neuroprotective activity and no BBB permeability, lower right 
quadrant represents low neuroprotective activity and high BBB 
permeability, upper left quadrant represents high neuroprotective 
activity and no BBB permeability and upper right quadrant 
represents high neuroprotective activity and high BBB permeability. 
 
4 Conclusion 
 
In summary, evaluation of the neuroprotective properties of 
structurally related methoxy flavones, hydroxy flavones and 
their 4-thio analogues has provided significant insights into 
the SARs of flavones, as summarised in Figure 7.  
 
 
Figure 7. Summary of the SARs on the neuroprotective activities of 
flavones. 
 
Overall, 7,8-dihydroxy 4-thioflavones such as compounds 
14d and 18d were found to exhibit potent neuroprotective 
effects against H2O2-induced oxidative stress with their 
activity being restored even at 0.3 µM concentration. For 14d 
and 18d, high BBB permeability is also predicted. 
Investigations of the molecular mechanism of action of 14d 
and 18d indicated that these compounds preferably mediate 
their neuroprotective effects through suppression of apoptosis 
by activating the anti-apoptotic proteins, and inactivating the 
pro-apoptotic proteins of the ERK1/2 and PI3K/Akt/mTOR 
pathways that are deregulated in AD48 and PD49. As such, 
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small molecules have been identified that confer 
neuroprotection against oxidative stress by activating pro-
survival regulatory pathways. Therefore, the synthetic 
flavones 14d and 18d can be considered as promising 
candidates for further optimisation and development as 
neuroprotective agents. In this regard, future studies that will 
decipher the pharmacokinetic and pharmacodynamic 
properties of these synthetic compounds will further guide the 
optimisation of these candidates for neuroprotective 
applications.  
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